Half-Life (Normalesrd) Hours
5-15/Unchanged
Plasma Protein Binding %
0
Volume Of Distribution L/Kg
0.4-1
Dose For Normal Renal Function
125 mg daily for 3 days
Second Dose
Second Dose: Titrate by 125 mg daily to maximum 750 mg bid
Adjustment For Renal Failure Method
I
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
q12h [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
q12-24h [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
q24h [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose after dialysis, [A]
Supplement For Dialysis [Recommendation Level]: Pd
PD: No data
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: No data, no longer available
References
Lee CS, Marbury TC, Perchalski RT, Wilder BJ. Pharmacokinetics of primidone elimination by uremic patients. J Clin Pharmacol. 1982; 22: 301-8. [PMID: 7107978] / Streete JM, Berry DJ, Jones JA, Groggin MJ. Clearance of phenylethylmalonamide during haemodialysis of a patient with renal failure. Ther Drug Monit. 1990; 12: 281-3.[PMID: 2349613]
Toxicity Notes
Excessive sedation. Nystagmus, folate deficiency. Partially converted to phenobarbital and other active metabolites with long half-life. Because of its complex kinetics and active metabolites, avoid primidone in patients with renal failure if possible.